Pricing Log in Create free account

Inhibrx Biosciences, Inc. (INBX) vs Rapport Therapeutics, Inc. (RAPP)

Inhibrx Biosciences, Inc. and Rapport Therapeutics, Inc. are both Biotechnology companies. Inhibrx Biosciences, Inc. and Rapport Therapeutics, Inc. are of similar size ($1.2B and $1.1B). Across the 8 metrics below, Inhibrx Biosciences, Inc. leads on 4 and Rapport Therapeutics, Inc. on 4.

Valuation

Metric INBX RAPP Biotechnology median
P/E n/m n/m 10.60
P/S 424.97 n/m 9.40
P/B n/m 2.99 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 438.60 n/m 9.02
Earnings yield (10.39%) (12.96%) (32.88%)
Free cash flow yield (9.85%) (10.33%) (23.13%)

Profitability

Metric INBX RAPP Biotechnology median
Gross margin 100.00% — 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (1,773.60%) (33.33%) (51.96%)
Return on assets (75.44%) (31.55%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric INBX RAPP Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) (108.03%) 24.34% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric INBX RAPP Biotechnology median
Debt to equity (3.33) 0.00 0.00
Current ratio 5.07 20.07 4.97
Net debt to EBITDA 0.18 3.91 1.01

Dividend

Metric INBX RAPP Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric INBX RAPP Biotechnology median
Market cap 1.18b 1.14b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack